Navigation Links
New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD
Date:12/3/2007

sleep medication that has shown no evidence of abuse or dependence in clinical studies,* and has not been designated as a controlled substance. With the exception of ROZEREM, all other prescription medications indicated for insomnia are classified as Schedule IV controlled substances by the U.S. Drug Enforcement Administration. ROZEREM has a unique therapeutic mechanism of action that targets MT1 and MT2 receptors. The activity at MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) is thought to promote sleep.

*ROZEREM is not a controlled substance. A clinical abuse liability study showed no differences indicative of abuse potential between ROZEREM and placebo at doses up to 20 times the recommended dose (N=14). Three 35-day insomnia studies showed no evidence of rebound insomnia or withdrawal symptoms with ROZEREM compared to placebo (N=2082).

Important Safety Information

ROZEREM(TM) should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression.

ROZEREM has not been studied in patients with severe sleep apnea or in children or adolescents. The effects in these populations are unknown. Avoid taking ROZEREM with alcohol. Studies for severe COPD have not yet been evaluated by the FDA. ROZEREM has been associated with decreased testosterone levels and increased prolactin levels. Health professionals should be mindful of any unexplained symptoms which could include cessation of menses or galactorrhea in females, decreased libido or problems with fertility that are possibly associated with such changes in these hormone levels. ROZEREM should not be taken with or immediately after a
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... MO (PRWEB) April 28, 2015 The ... 2015 from 5:00 to 8:00 pm at the Sheraton Colonial ... than 50 hospitals, clinics and groups with career opportunities will ... represented. Attendees will enjoy free hors d’oeuvres and raffle prize ... PracticeMatch says “Boston is an ideal location to hold ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 The west ... are among the top areas that healthcare professionals searched ... aureusmedical.com, during the month of March 2015. Data ... in travel nurse jobs , physical therapy ... within nursing and allied health fields. , ...
(Date:4/28/2015)... Foot and Ankle Specialists of the ... ( Annapolis and Clarksville Divisions ) was recently ... Maryland Podiatric Medical Association meeting on April 15, 2015. ... 1992 with a Bachelor of Arts in Life Sciences. ... soccer, track and cross-country. He then attended the New ...
(Date:4/27/2015)... VA (PRWEB) April 28, 2015 Medical ... **Presented by FDAnews and Ombu Enterprises**, June 16-17, 2015 ... an FDA inspector came to a facility today, would ... , If the answer is "maybe" or "no" … ... Enterprises and FDAnews have a solution. , Take ...
(Date:4/27/2015)... April 27, 2015 A new type of ... May 9. Science on Tap at the Science Museum of ... brews, but adds science hops for a bold, new flavor. ... trucks and serves up the science behind these frothy beverages. ... a first-hand look at the ingredients that go into beer ...
Breaking Medicine News(10 mins):Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 2Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 3Health News:Hot States for Medical Careers: Healthcare Staffing Agency Aureus Medical Releases Online Search Results 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Podiatrist Receives Maryland Podiatric Medical Association Outstanding Service Award 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4Health News:Science on Tap at the Science Museum of Virginia 2
... KUNMING, China, Nov. 16 /PRNewswire-Asia-FirstCall/ -- ... Shenghuo" or,the "Company"), which is engaged in the research, ... products,in the People,s Republic of China ("PRC"), today reported ... 2009. , , Third Quarter 2009 ...
... resonance images (MRI) of patients diagnosed with multiple sclerosis ... more aggressive, and causes more brain lesions, than MS ... have reported. , Interestingly, however, patients with pediatric-onset MS ... MS cases -- develop disabilities at a slower pace ...
... to treatment for chlamydia, gonorrhea, syphilis is ,imperative, expert ... girls aged 15 to 19 accounted for the largest ... gonorrhea cases in the United States in 2008, followed ... annual federal report released Monday. , The researchers also ...
... ... to grant an ill child’s dream to go to Disneyland , ... (PRWEB) November 16, 2009 -- LeapFish has ... that dream come true. Tweet-a-Cause, a social media fundraising initative, will give Twitter users the ...
... 16 The nation,s premier public health agency, the Centers ... contract with Georgia Power to purchase renewable energy for its ... http://www.newscom.com/cgi-bin/prnh/20050216/CLW066LOGO ) , The purchase of more than ... organization,s annual kilowatt-hour consumption, will make the CDC Georgia Power,s ...
... A powerful new breast cancer treatment could result ... cancer,s hallmark wild growth with another that blocks a ... part of itself, researchers say. While they are ... called histone deacetylase inhibitors, or HDAC inhibitors, also increase ...
Cached Medicine News:Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 2Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 3Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 4Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 5Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 6Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 7Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 8Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 9Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 10Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 11Health News:MS is more aggressive in children but slower to cause disability than in adults 2Health News:MS is more aggressive in children but slower to cause disability than in adults 3Health News:Teen Girls at Higher Risk for STDs: Report 2Health News:LeapFish and Make-a-Wish Foundation Join Forces to Raise $10,000 and Tweet an Ill Child's Wish True 2Health News:Georgia Power, Centers for Disease Control and Prevention Forge Green Energy Partnership 2Health News:New combination therapy could deliver powerful punch to breast cancer 2
(Date:4/28/2015)... EVERETT, Wash. , April 28, 2015  Unfors ... released a new radiation Survey sensor aimed at expanding ... The RaySafe X2 Survey sensor is the easiest and ... energy range. It is the latest addition to the ... the ability to perform leakage and scatter measurements in ...
(Date:4/28/2015)... -- Shares of Celladon Corp. (NASDAQ: CLDN ) lost ... of poor drug trial results of the phase 2B CUPID2 ... The selloff may be warranted or it may be ... prices. An analyst report update on CLDN ... review, analyst summary, valuation, and recommendation can be viewed ...
(Date:4/27/2015)... MARIETTA, Ga., April 27, 2015  MiMedx Group, ... medicine company utilizing human amniotic tissue and patent-protected ... therapies for the Wound Care, Surgical, Orthopedic, Spine, ... announced today its record results for the first ... also announced today the decision of its Board ...
Breaking Medicine Technology:Unfors RaySafe, a Fluke Biomedical company, unveils a new Survey sensor for the RaySafe X2 2Examining what's Left after MYDICAR Drug Trial Ends In Failure; Celladon Corp. Analyst Report Issued by BrokerBank Securities, Inc. 2MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 2MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 3MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 4MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 5MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 6MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 7MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 8MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 9MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 10MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 11MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 12MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 13MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 14
... ,SARAH, - a French national collaborative randomized controlled ... sorafenib in advanced hepatocellular carcinoma is now open ... a new randomized controlled trial to directly compare ... (SIR-Spheres ® microspheres; Sirtex Medical Limited, Australia) ...
... 2, 2012  On February 2, at the Late-Breaking Science Session ... the TREVO Study ( T hrombectomy ... O cclusions in acute ischemic stroke). This ... clot-removing stent retriever technology. Sixty patients were enrolled by seven ...
Cached Medicine Technology:New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 2New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 3New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 4Stryker Presents Results of the TREVO Prospective Clinical Study at the International Stroke Conference 2
MultiWash Advantage is a versatile microplate washer engineered for reliability. It is designed for lab environments to help streamline their daily processes....
... for the determination of A1c is also designed ... Plus is a fully automated analyzer including primary ... ultimate in safety and positive identification. The analysis ... to be interference-free and to produce the lowest ...
... Maximize your laboratorys productivity ... enhanced automated workflow management. ... automated workstation now completely ... immunoassay with specimen processing ...
... The STart 4 semi-automated hemostasis analyzer ... electro-mechanical clot detection (Viscosity-based Detection System). ... icteric or other optically turbid samples ... offers programmable and preprogrammed assays with ...
Medicine Products: